forbes article on dendreon, page-3

Really, first I've heard of that. That is a long long way of and I wonder how Dendreon feel about that as any agreement, contract or otherwise with another company would possibly restrict their output, and in the early stages of producing Provenge they are running well below future targets.

That is very interesting, but the last I heard was that Prima expect either licencing with or take over by large pharma as the most likely outcome and therefore maybe no need for Dendreons facilities. I would be very happy though to see Prima partner with Dendreon for its future US operations if succcessful.

Thanks for the info, but can you please advise where you got it from.